TY - JOUR
T1 - Impact of myc on anti-tumor immune responses in aggressive b cell non-hodgkin lymphomas: Consequences for cancer immunotherapy
AU - Vera de Jonge, A.
AU - Mutis, Tuna
AU - Roemer, Margaretha G. M.
AU - Scheijen, Blanca
AU - Chamuleau, Martine E. D.
N1 - Funding Information: Conflicts of Interest: Authors declare no conflict of interest; A.V.d.J. and M.G.M.R. have nothing to disclose. T.M. received research support from Janssen Pharmaceuticals, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Aduro and Onkimmune; B.S. received research funding from Dutch Cancer Society (KWF Kankerbestrijding, grant 11137); M.E.D.C. received research funding from BMS, Celgene, Gilead and GenMab. Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Patients with MYC overexpressing high grade B cell lymphoma (HGBL) face significant dismal prognosis after treatment with standard immunochemotherapy regimens. Recent preclinical studies indicate that MYC not only contributes to tumorigenesis by its effects on cell proliferation and differentiation, but also plays an important role in promoting escape from anti-tumor immune responses. This is of specific interest, since reversing tumor immune inhibition with immunotherapy has shown promising results in the treatment of both solid tumors and hematological malignancies. In this review, we outline the current understanding of impaired immune responses in B cell lymphoid malignancies with MYC overexpression, with a particular emphasis on diffuse large B cell lymphoma. We also discuss clinical consequences of MYC overexpression in the treatment of HGBL with novel immunotherapeutic agents and potential future treatment strategies.
AB - Patients with MYC overexpressing high grade B cell lymphoma (HGBL) face significant dismal prognosis after treatment with standard immunochemotherapy regimens. Recent preclinical studies indicate that MYC not only contributes to tumorigenesis by its effects on cell proliferation and differentiation, but also plays an important role in promoting escape from anti-tumor immune responses. This is of specific interest, since reversing tumor immune inhibition with immunotherapy has shown promising results in the treatment of both solid tumors and hematological malignancies. In this review, we outline the current understanding of impaired immune responses in B cell lymphoid malignancies with MYC overexpression, with a particular emphasis on diffuse large B cell lymphoma. We also discuss clinical consequences of MYC overexpression in the treatment of HGBL with novel immunotherapeutic agents and potential future treatment strategies.
KW - Diffuse large B cell lymphoma
KW - High grade B cell lymphoma
KW - Immunotherapy
KW - MYC
KW - MYC inhibition
KW - T cell therapy
KW - Tumor immune evasion
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85093645694&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/33092116
U2 - https://doi.org/10.3390/cancers12103052
DO - https://doi.org/10.3390/cancers12103052
M3 - Review article
C2 - 33092116
SN - 2072-6694
VL - 12
SP - 1
EP - 21
JO - Cancers
JF - Cancers
IS - 10
M1 - 3052
ER -